Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
NCT00069758
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG:
SDX-105
Sponsor
Cephalon